ReviewHaematologica2020
The never ending success story of tranexamic acid in acquired bleeding.
Review in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Tranexamic Acid Administration in Laparoscopic Sleeve Gastrectomy.Obesity surgery · 2026Pooled it
- Tranexamic Acid for Acute Spontaneous Intracerebral Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.Frontiers in neurology · 2021Pooled it
- Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study.British journal of anaesthesia · 2022Trial
- Red Blood Cells and Tranexamic Acid in the Inhibition of Fibrinolysis.Seminars in thrombosis and hemostasis · 2026Review
- Inherited Platelet Disorders During Pregnancy and Delivery: Overview of Management Strategies and Emerging Therapeutic Considerations.Hematology reports · 2026Review
- Tranexamic Acid in Pediatric Care: A Comprehensive Overview.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Effect of Tranexamic Acid Administration on the State of Pial Arterial Vessels in Rats with Acute Hemorrahage and Hypothermia.Bulletin of experimental biology and medicine · 2025Article
- Critical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study.Blood advances · 2025Article
- Article
- Tranexamic acid - a promising hemostatic agent with limitations: a narrative review.Korean journal of anesthesiology · 2024Review
- Fibrinolytic-deficiencies predispose hosts to septicemia from a catheter-associated UTI.Nature communications · 2024Article
- Intrapulmonary administration of recombinant activated factor VII in pediatric, adolescent, and young adult oncology and hematopoietic cell transplant patients with pulmonary hemorrhage.Frontiers in oncology · 2024Article
- Review
- Tranexamic acid: a narrative review of its current role in perioperative medicine and acute medical bleeding.Frontiers in medicine · 2024Review
- Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient.Anesthesiology · 2023Article
- Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.Blood advances · 2023Article
- The usefulness of tranexamic acid for bleeding symptoms of chronic consumptive coagulopathy complicated by aortic disease: a single-institute, retrospective study of 14 patients.Thrombosis journal · 2023Article
- Microcluster colloidosomes for hemostat delivery into complex wounds: A platform inspired by the attack action of torpedoes.Bioactive materials · 2022Article
- In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.Research and practice in thrombosis and haemostasis · 2022Article
- Treatment of inherited thrombocytopenias.Haematologica · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen activation and fibrinolysis. Although its first clinical use dates back more than 50 years, this hemostatic agent is still the object of intense clinical and developmental research. In particular, renewed interest in TXA has arisen following evidence that it has a beneficial effect in reducing blood loss in a variety of medical and surgical conditions at increased risk of bleeding. Given this characteristic, TXA is currently considered a mainstay of Patient Blood Management programs aimed at reducing patients' exposure to allogeneic blood transfusion. Importantly, recent large randomized controlled trials have consistently documented that the use of TXA confers a survival advantage in a number of globally critical clinical conditions associated with acute bleeding, including traumatic injury and post-partum hemorrhage, without increasing the thromboembolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.